Analogous results were obtained from a clinical trial (NCT01638546) on a pooled cohort of 94 SCLC patients treated with either an alkylating agent, Temozolomide, and/or a poly(ADP-ribose) polymerase 1 (PARP) inhibitor (Veliparib). This evidence concerns the gene PARP1 and small cell lung carcinoma.